UCB Group (UCBJF.PK) And Sanofi-Aventis (France) (SASY.PA) Sign A Co-Promotion Agreement For Xyzal(R); In The United States  
9/25/2006 4:44:18 PM

BRUSSELS, BELGIUM -- (MARKET WIRE) -- September 25, 2006 -- UCB and sanofi-aventis announced today that they have entered into an agreement to co-promote in the United States the prescription antihistamine medicine, Xyzal® (levocetirizine dihydrochloride). Xyzal® is a once-daily antihistamine which was first launched in Europe in 2001 and currently marketed in 49 countries around the world where it enjoys leadership position in key markets.